Interleukin 17a Antikörper

Produktnummer ABIN2665115

Dieses Anti-Interleukin 17a-Antikörper ist ein Ratte Monoklonal-Antikörper zur Detektion von Interleukin 17a in FACS. Geeignet für Maus.

Kurzübersicht für Interleukin 17a Antikörper (ABIN2665115)

Target: Interleukin 17a (IL17A) (Interleukin 17A (IL17A))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser Interleukin 17a Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: TC11-18H10-1

Produktdetails anti-Interleukin 17a Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and EDTA.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu Interleukin 17a

Target: Interleukin 17a (IL17A) (Interleukin 17A (IL17A))

Andere Bezeichnung: IL-17A

Hintergrund: IL-17, also known as CTLA-8, is a T cell-expressed pleiotropic cytokine that exhibits a high degree of homology to a protein encoded by the ORF13 gene of herpes virus Saimiri. IL-17 is produced by Th cells (Th17) that are distinct from the traditional Th1- and Th2-cell subsets. IL-23 plays an important role in triggering IL-17 production. Both recombinant and natural IL-17 have been shown to exist as disulfide linked homodimers. IL-17 exhibits multiple biological activities on a variety of cells including: the induction of IL-6 and IL-8 production in fibroblasts, activation of NF-κB, and costimulation of T cell proliferation. IL-17 is an essential inflammatory mediator in the development of autoimmune diseases. Neutralization of IL-17 with monoclonal antibody is able to ameliorate the disease course.